Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.Data published in Clinical Cancer Research revealed no statistically significant differences in efficacy outcomes according to race and no additional treatment-related adverse events.
